guest ::
| Home > Publications Database > [Neurological side effects of checkpoint inhibitors]. > print |
| 001 | 140487 | ||
| 005 | 20240109101331.0 | ||
| 024 | 7 | _ | |a 10.1007/s00115-018-0571-8 |2 doi |
| 024 | 7 | _ | |a pmid:30073487 |2 pmid |
| 024 | 7 | _ | |a 0028-2804 |2 ISSN |
| 024 | 7 | _ | |a 1433-0407 |2 ISSN |
| 024 | 7 | _ | |a altmetric:46026894 |2 altmetric |
| 037 | _ | _ | |a DZNE-2020-06809 |
| 041 | _ | _ | |a ger |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Knauss, S. |b 0 |
| 245 | _ | _ | |a [Neurological side effects of checkpoint inhibitors]. |
| 260 | _ | _ | |a Heidelberg |c 2019 |b Springer |
| 264 | _ | 1 | |3 online |2 Crossref |b Springer Science and Business Media LLC |c 2018-08-02 |
| 264 | _ | 1 | |3 print |2 Crossref |b Springer Science and Business Media LLC |c 2019-02-01 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1704791226_29463 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a In recent years the treatment of many tumor entities has been revolutionized by the use of modern immunotherapies with checkpoint inhibitors; however, good response rates are contrasted by many immune-mediated side effects. Neurological immune-mediated side effects are rare but often severe complications of checkpoint inhibitor treatment.A systematic search in the PubMed and Web of Sciences databases was carried out for case reports and studies on neurological side effects during checkpoint inhibitor treatment.A total of 42 articles on neurological side effects of checkpoint inhibitors with a total of 85 reported cases could be identified. The most frequently reported neurological side effects were myopathies, neuropathies, diseases of the neuromuscular endplates and encephalitides. Among those, encephalitides and myopathies with accompanying myocarditis were associated with the highest morbidity and mortality.Against the background of a rapidly increasing use of checkpoint inhibitors, this article provides an overview of currently available reports on the clinical courses of neurological side effects. Controlled studies on the treatment of neurological side effects are lacking. From case studies it can be assumed that early steroid treatment increases the probability of a complete remission of neurological symptoms. Typical symptom constellations must therefore be rapidly recognized and an immunosuppressive treatment must be initiated. |
| 536 | _ | _ | |a 344 - Clinical and Health Care Research (POF3-344) |0 G:(DE-HGF)POF3-344 |c POF3-344 |f POF III |x 0 |
| 542 | _ | _ | |i 2018-08-02 |2 Crossref |u http://www.springer.com/tdm |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Antineoplastic Agents, Immunological |2 NLM Chemicals |
| 650 | _ | 2 | |a Antineoplastic Agents, Immunological: adverse effects |2 MeSH |
| 650 | _ | 2 | |a Antineoplastic Agents, Immunological: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a Drug-Related Side Effects and Adverse Reactions |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Immunotherapy |2 MeSH |
| 650 | _ | 2 | |a Neoplasms: therapy |2 MeSH |
| 650 | _ | 2 | |a Nervous System Diseases: chemically induced |2 MeSH |
| 700 | 1 | _ | |a Ginesta Roque, L. |b 1 |
| 700 | 1 | _ | |a Hühnchen, P. |b 2 |
| 700 | 1 | _ | |a Heinzerling, L. |b 3 |
| 700 | 1 | _ | |a Böhmerle, W. |0 P:(DE-HGF)0 |b 4 |e Corresponding author |
| 700 | 1 | _ | |a Endres, M. |0 P:(DE-2719)2811033 |b 5 |e Last author |u dzne |
| 773 | 1 | 8 | |a 10.1007/s00115-018-0571-8 |b : Springer Science and Business Media LLC, 2018-08-02 |n 2 |p 138-147 |3 journal-article |2 Crossref |t Der Nervenarzt |v 90 |y 2018 |x 0028-2804 |
| 773 | _ | _ | |a 10.1007/s00115-018-0571-8 |g Vol. 90, no. 2, p. 138 - 147 |0 PERI:(DE-600)1462945-8 |n 2 |q 90:2<138 - 147 |p 138-147 |t Der Nervenarzt |v 90 |y 2019 |x 0028-2804 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/140487/files/DZNE-2020-06809.pdf |
| 856 | 4 | _ | |u https://pub.dzne.de/record/140487/files/DZNE-2020-06809.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |p VDB |o oai:pub.dzne.de:140487 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)2811033 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-344 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2019 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-12 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NERVENARZT : 2021 |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-12 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-12 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2022-11-12 |
| 920 | 1 | _ | |0 I:(DE-2719)1811005 |k AG Endres |l Interdisciplinary Dementia Research |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1811005 |
| 980 | _ | _ | |a UNRESTRICTED |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1177/1078155215572932 |2 Crossref |o 10.1177/1078155215572932 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/CJI.0b013e318193a206 |2 Crossref |o 10.1097/CJI.0b013e318193a206 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1136/practneurol-2012-000447 |2 Crossref |o 10.1136/practneurol-2012-000447 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1200/JCO.2016.66.6552 |2 Crossref |o 10.1200/JCO.2016.66.6552 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/COC.0000000000000239 |2 Crossref |o 10.1097/COC.0000000000000239 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1186/s13104-015-1283-9 |2 Crossref |o 10.1186/s13104-015-1283-9 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/MD.0000000000007350 |2 Crossref |o 10.1097/MD.0000000000007350 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1158/2326-6066.CIR-15-0035 |2 Crossref |o 10.1158/2326-6066.CIR-15-0035 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/S1470-2045(15)70122-1 |2 Crossref |o 10.1016/S1470-2045(15)70122-1 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/j.ejso.2016.07.145 |2 Crossref |o 10.1016/j.ejso.2016.07.145 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/CJI.0b013e31827807dd |2 Crossref |o 10.1097/CJI.0b013e31827807dd |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1002/ana.24715 |2 Crossref |o 10.1002/ana.24715 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1177/1352458514549403 |2 Crossref |o 10.1177/1352458514549403 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/j.nmd.2017.01.002 |2 Crossref |o 10.1016/j.nmd.2017.01.002 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/j.ejca.2016.12.038 |2 Crossref |o 10.1016/j.ejca.2016.12.038 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/CCO.0000000000000358 |2 Crossref |o 10.1097/CCO.0000000000000358 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1186/s40425-016-0152-y |2 Crossref |o 10.1186/s40425-016-0152-y |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1056/NEJMoa1609214 |2 Crossref |o 10.1056/NEJMoa1609214 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1200/JCO.2013.51.1683 |2 Crossref |o 10.1200/JCO.2013.51.1683 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1146/annurev.immunol.26.021607.090331 |2 Crossref |o 10.1146/annurev.immunol.26.021607.090331 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1111/cas.12961 |2 Crossref |o 10.1111/cas.12961 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1055/s-0033-1355337 |2 Crossref |o 10.1055/s-0033-1355337 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1056/NEJMoa1504030 |2 Crossref |o 10.1056/NEJMoa1504030 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1634/theoncologist.2016-0487 |2 Crossref |o 10.1634/theoncologist.2016-0487 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1002/mus.25141 |2 Crossref |o 10.1002/mus.25141 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.3389/fimmu.2018.00108 |2 Crossref |o 10.3389/fimmu.2018.00108 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1093/neuonc/nou001 |2 Crossref |o 10.1093/neuonc/nou001 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1002/mus.24648 |2 Crossref |o 10.1002/mus.24648 |
| 999 | C | 5 | |y 2016 |2 Crossref |o O Maeda 2016 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/j.jacc.2018.02.037 |2 Crossref |o 10.1016/j.jacc.2018.02.037 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1056/NEJMc1515584 |2 Crossref |o 10.1056/NEJMc1515584 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/j.jns.2014.06.023 |2 Crossref |o 10.1016/j.jns.2014.06.023 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1002/mus.23830 |2 Crossref |o 10.1002/mus.23830 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1093/annonc/mdw181 |2 Crossref |o 10.1093/annonc/mdw181 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/CMR.0000000000000310 |2 Crossref |o 10.1097/CMR.0000000000000310 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1007/s00415-008-0783-0 |2 Crossref |o 10.1007/s00415-008-0783-0 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.3109/09273948.2014.1001858 |2 Crossref |o 10.3109/09273948.2014.1001858 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1002/mus.25163 |2 Crossref |o 10.1002/mus.25163 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/S1470-2045(15)00083-2 |2 Crossref |o 10.1016/S1470-2045(15)00083-2 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1158/1078-0432.CCR-12-3080 |2 Crossref |o 10.1158/1078-0432.CCR-12-3080 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1155/2017/1093858 |2 Crossref |o 10.1155/2017/1093858 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1136/bcr-2016-215012 |2 Crossref |o 10.1136/bcr-2016-215012 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1159/000477162 |2 Crossref |o 10.1159/000477162 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.2340/00015555-2548 |2 Crossref |o 10.2340/00015555-2548 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1002/mus.25212 |2 Crossref |o 10.1002/mus.25212 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1177/1010428317695013 |2 Crossref |o 10.1177/1010428317695013 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1093/jjco/hyv158 |2 Crossref |o 10.1093/jjco/hyv158 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1093/annonc/mdw558 |2 Crossref |o 10.1093/annonc/mdw558 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/MAJ.0000000000000584 |2 Crossref |o 10.1097/MAJ.0000000000000584 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/CJI.0000000000000190 |2 Crossref |o 10.1097/CJI.0000000000000190 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1093/jjco/hyw090 |2 Crossref |o 10.1093/jjco/hyw090 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/CJI.0000000000000177 |2 Crossref |o 10.1097/CJI.0000000000000177 |
| 999 | C | 5 | |2 Crossref |o |
| 999 | C | 5 | |y 2017 |2 Crossref |o U.S. Food and Drug Administration 2017 |
| 999 | C | 5 | |y 2017 |2 Crossref |t Common terminology criteria for adverse events (CTCAE) v5.0 |o Department of Health Common terminology criteria for adverse events (CTCAE) v5.0 2017 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1126/science.aad1329 |2 Crossref |o 10.1126/science.aad1329 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1371/journal.pone.0053745 |2 Crossref |o 10.1371/journal.pone.0053745 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/S1470-2045(15)70076-8 |2 Crossref |o 10.1016/S1470-2045(15)70076-8 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1001/jamaneurol.2016.1399 |2 Crossref |o 10.1001/jamaneurol.2016.1399 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/CJI.0b013e318156e47e |2 Crossref |o 10.1097/CJI.0b013e318156e47e |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1002/mus.25055 |2 Crossref |o 10.1002/mus.25055 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.3171/2016.8.PEDS16326 |2 Crossref |o 10.3171/2016.8.PEDS16326 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/j.ejca.2016.02.024 |2 Crossref |o 10.1016/j.ejca.2016.02.024 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1007/s10637-011-9787-1 |2 Crossref |o 10.1007/s10637-011-9787-1 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1634/theoncologist.2016-0366 |2 Crossref |o 10.1634/theoncologist.2016-0366 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1056/NEJMra1514296 |2 Crossref |o 10.1056/NEJMra1514296 |
| 999 | C | 5 | |y 2011 |2 Crossref |t MDX-010 antibody, MDX-1379 melanoma vaccine, or MDX-010/MDX-1379 combination treatment for patients with unresectable or metastatic melanoma |o ClinicalTrials.gov MDX-010 antibody, MDX-1379 melanoma vaccine, or MDX-010/MDX-1379 combination treatment for patients with unresectable or metastatic melanoma 2011 |
| 999 | C | 5 | |y 2017 |2 Crossref |t Efficacy study of Ipilimumab versus placebo to prevent recurrence after complete resection of high risk stage III melanom |o ClinicalTrials.gov Efficacy study of Ipilimumab versus placebo to prevent recurrence after complete resection of high risk stage III melanom 2017 |
| 999 | C | 5 | |y 2017 |2 Crossref |t A study to compare BMS-936558 to the physician’s choice of either dacarbazine or carboplatin and paclitaxel in advanced melanoma patients that have progressed following anti-CTLA-4 therapy (checkmate 037) |o ClinicalTrials.gov A study to compare BMS-936558 to the physician’s choice of either dacarbazine or carboplatin and paclitaxel in advanced melanoma patients that have progressed following anti-CTLA-4 therapy (checkmate 037) 2017 |
| 999 | C | 5 | |y 2017 |2 Crossref |t Study of Nivolumab (BMS-936558) compared with dacarbazine in untreated, unresectable, or metastatic melanoma (checkmate 066) |o ClinicalTrials.gov Study of Nivolumab (BMS-936558) compared with dacarbazine in untreated, unresectable, or metastatic melanoma (checkmate 066) 2017 |
| 999 | C | 5 | |y 2016 |2 Crossref |t Trial of nivolumab vs therapy of investigator’s choice in recurrent or metastatic head and neck carcinoma (checkmate 141) |o ClinicalTrials.gov Trial of nivolumab vs therapy of investigator’s choice in recurrent or metastatic head and neck carcinoma (checkmate 141) 2016 |
| 999 | C | 5 | |y 2017 |2 Crossref |t A study of pembrolizumab (MK-3475) in participants with recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma (MK-3475-059/KEYNOTE-059) |o ClinicalTrials.gov A study of pembrolizumab (MK-3475) in participants with recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma (MK-3475-059/KEYNOTE-059) 2017 |
| 999 | C | 5 | |y 2017 |2 Crossref |t A study of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for participants with advanced urothelial cancer (MK-3475-045/KEYNOTE-045) |o ClinicalTrials.gov A study of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for participants with advanced urothelial cancer (MK-3475-045/KEYNOTE-045) 2017 |
| 999 | C | 5 | |y 2018 |2 Crossref |t Nivolumab combined with Ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma (checkmate 214) |o ClinicalTrials.gov Nivolumab combined with Ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma (checkmate 214) 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t Study of BMS-936558 (Nivolumab) compared to docetaxel in previously treated metastatic non-squamous NSCLC (checkmate057) |o ClinicalTrials.gov Study of BMS-936558 (Nivolumab) compared to docetaxel in previously treated metastatic non-squamous NSCLC (checkmate057) 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t Study of nivolumab (BMS-936558) vs. everolimus in pre-treated advanced or metastatic clear-cell renal cell carcinoma (checkmate 025) |o ClinicalTrials.gov [Internet] Bethesda (MD): National Library of Medicine (US) Study of nivolumab (BMS-936558) vs. everolimus in pre-treated advanced or metastatic clear-cell renal cell carcinoma (checkmate 025) 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t Phase 3 study of nivolumab or nivolumab plus Ipilimumab versus Ipilimumab alone in previously untreated advanced melanoma (checkmate 067) |o ClinicalTrials.gov Phase 3 study of nivolumab or nivolumab plus Ipilimumab versus Ipilimumab alone in previously untreated advanced melanoma (checkmate 067) 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t An Immuno-therapy study to evaluate the effectiveness, safety and tolerability of nivolumab or nivolumab in combination with other agents in patients with advanced liver cancer (checkmate040) |o ClinicalTrials.gov An Immuno-therapy study to evaluate the effectiveness, safety and tolerability of nivolumab or nivolumab in combination with other agents in patients with advanced liver cancer (checkmate040) 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t An investigational immuno-therapy study of nivolumab, and nivolumab in combination with other anti-cancer drugs, in colon cancer that has come back or has spread (checkmate142) |o ClinicalTrials.gov An investigational immuno-therapy study of nivolumab, and nivolumab in combination with other anti-cancer drugs, in colon cancer that has come back or has spread (checkmate142) 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t A study of nivolumab in participants with metastatic or unresectable bladder cancer |o ClinicalTrials.gov A study of nivolumab in participants with metastatic or unresectable bladder cancer 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t Study of nivolumab in patients with classical Hodgkin’s lymphoma (registrational) (checkmate 205) |o ClinicalTrials.gov Study of nivolumab in patients with classical Hodgkin’s lymphoma (registrational) (checkmate 205) 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t Efficacy study of nivolumab compared to Ipilimumab in prevention of recurrence of melanoma after complete resection of stage IIIb/c or stage IV melanoma (checkmate 238) |o ClinicalTrials.gov Efficacy study of nivolumab compared to Ipilimumab in prevention of recurrence of melanoma after complete resection of stage IIIb/c or stage IV melanoma (checkmate 238) 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t Study of BMS-936558 (Nivolumab) compared to docetaxel in previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC) (checkmate 017) |o ClinicalTrials.gov Study of BMS-936558 (Nivolumab) compared to docetaxel in previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC) (checkmate 017) 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t Study to evaluate the safety and efficacy of two different dosing schedules of pembrolizumab (MK-3475) compared to Ipilimumab in participants with advanced melanoma (MK-3475-006/KEYNOTE-006) |o ClinicalTrials.gov Study to evaluate the safety and efficacy of two different dosing schedules of pembrolizumab (MK-3475) compared to Ipilimumab in participants with advanced melanoma (MK-3475-006/KEYNOTE-006) 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) |o ClinicalTrials.gov Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t Study of pembrolizumab (MK-3475) in participants with advanced solid tumors (MK-3475-012/KEYNOTE-012) |o ClinicalTrials.gov Study of pembrolizumab (MK-3475) in participants with advanced solid tumors (MK-3475-012/KEYNOTE-012) 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) |o ClinicalTrials.gov Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t Study of pembrolizumab (MK-3475) in participants with advanced solid tumors (MK-3475-028/KEYNOTE-28) |o ClinicalTrials.gov Study of pembrolizumab (MK-3475) in participants with advanced solid tumors (MK-3475-028/KEYNOTE-28) 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t Study of pembrolizumab (MK-3475) as monotherapy in participants with previously-treated locally advanced unresectable or metastatic colorectal cancer (MK-3475-164/KEYNOTE-164) |o ClinicalTrials.gov Study of pembrolizumab (MK-3475) as monotherapy in participants with previously-treated locally advanced unresectable or metastatic colorectal cancer (MK-3475-164/KEYNOTE-164) 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t Phase 2 study of MK-3475 in patients with microsatellite unstable (MSI) tumors |o ClinicalTrials.gov Phase 2 study of MK-3475 in patients with microsatellite unstable (MSI) tumors 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t Study of pembrolizumab (MK-3475) in participants with advanced urothelial cancer (MK-3475-052/KEYNOTE-52) |o ClinicalTrials.gov Study of pembrolizumab (MK-3475) in participants with advanced urothelial cancer (MK-3475-052/KEYNOTE-52) 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t Study of pembrolizumab (MK-3475) in participants with relapsed or refractory classical Hodgkin lymphoma (MK-3475-087/KEYNOTE-087) |o ClinicalTrials.gov Study of pembrolizumab (MK-3475) in participants with relapsed or refractory classical Hodgkin lymphoma (MK-3475-087/KEYNOTE-087) 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t Study of two doses of pembrolizumab (MK-3475) versus docetaxel in previously treated participants with non-small cell lung cancer (MK-3475-010/KEYNOTE-010) |o ClinicalTrials.gov Study of two doses of pembrolizumab (MK-3475) versus docetaxel in previously treated participants with non-small cell lung cancer (MK-3475-010/KEYNOTE-010) 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t A study of atezolizumab compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer who have failed platinum-containing therapy (OAK) |o ClinicalTrials.gov A study of atezolizumab compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer who have failed platinum-containing therapy (OAK) 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t A study of atezolizumab in participants with locally advanced or metastatic urothelial bladder cancer (cohort 1) |o ClinicalTrials.gov A study of atezolizumab in participants with locally advanced or metastatic urothelial bladder cancer (cohort 1) 2018 |
| 999 | C | 5 | |y 2018 |2 Crossref |t Avelumab in metastatic or locally advanced solid tumors (JAVELIN solid tumor) |o ClinicalTrials.gov Avelumab in metastatic or locally advanced solid tumors (JAVELIN solid tumor) 2018 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1002/eji.201646875 |2 Crossref |o 10.1002/eji.201646875 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/j.ctrv.2017.01.008 |2 Crossref |o 10.1016/j.ctrv.2017.01.008 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1158/2326-6066.CIR-15-0141 |2 Crossref |o 10.1158/2326-6066.CIR-15-0141 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1159/000362614 |2 Crossref |o 10.1159/000362614 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.20517/2394-4722.2017.41 |2 Crossref |o 10.20517/2394-4722.2017.41 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/CJI.0000000000000070 |2 Crossref |o 10.1097/CJI.0000000000000070 |
| 999 | C | 5 | |y 2011 |2 Crossref |t YERVOY highlights of prescribing information |o U.S. Food and Drug Administration YERVOY highlights of prescribing information 2011 |
| 999 | C | 5 | |y 2017 |2 Crossref |t BAVENCIO highlights of prescribing information |o U.S. Food and Drug Administration BAVENCIO highlights of prescribing information 2017 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1093/annonc/mdr028 |2 Crossref |o 10.1093/annonc/mdr028 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|